atazanavir sulfate has been researched along with hydroxychloroquine in 6 studies
| Studies (atazanavir sulfate) | Trials (atazanavir sulfate) | Recent Studies (post-2010) (atazanavir sulfate) | Studies (hydroxychloroquine) | Trials (hydroxychloroquine) | Recent Studies (post-2010) (hydroxychloroquine) |
|---|---|---|---|---|---|
| 1,102 | 246 | 590 | 5,885 | 474 | 4,041 |
| Protein | Taxonomy | atazanavir sulfate (IC50) | hydroxychloroquine (IC50) |
|---|---|---|---|
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 2.951 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 4.772 | |
| Toll-like receptor 9 | Homo sapiens (human) | 0.11 | |
| Toll-like receptor 7 | Homo sapiens (human) | 3.4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 6 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshar, H; Aloosh, O; Emamikhah, M; Kalantari, S; Lotfi, T; Moghaddasi, M; Sadeghipour, A; Yassin, Z | 1 |
| Abbasian, L; Davoudi-Monfared, E; Hajiabdolbaghi, M; Kazemzadeh, H; Khalili, H; Rahmani, H; Salehi, M; Yekaninejad, MS | 1 |
| Abbasian, L; Davoudi-Monfared, E; Ghaderkhani, S; Ghiasvand, F; Hasannezhad, M; Khalili, H; Mohammadi, M; Nabiee, M; Nourian, A; Rahmani, H; Sadeghi, S; Seifi, A; Yekaninejad, MS | 1 |
| Alimohamadi, Y; Fard, SR; Kalantari, S; Maleki, D; Minaeian, S; Taher, MT; Yassin, Z | 1 |
| Abdi, A; Bavand, A; Farahani, E; Mazaherpour, H; Mazaherpour, S; Ramezani, A; Sofian, M | 1 |
| Atefi, N; Baghestani, A; Goodarzi, A; Khodabandehloo, N; Mahdi, Z; Najar Nobari, N; Riahi, T; Seirafianpour, F; Talebi Taher, M; Valizadeh, R | 1 |
3 trial(s) available for atazanavir sulfate and hydroxychloroquine
| Article | Year |
|---|---|
A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19.
Topics: Adult; Aged; Antiviral Agents; Atazanavir Sulfate; Betacoronavirus; Cardiovascular Diseases; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Dyslipidemias; Female; Humans; Hydroxychloroquine; Intensive Care Units; Interferon beta-1a; Length of Stay; Lopinavir; Male; Middle Aged; Neoplasms; Pandemics; Patient Safety; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Survival Analysis; Treatment Outcome | 2020 |
Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients.
Topics: Antiviral Agents; Atazanavir Sulfate; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; Humans; Hydroxychloroquine; Lopinavir; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Ritonavir; Treatment Outcome | 2021 |
Evaluation of the efficacy and safety of oral N-acetylcysteine in patients with COVID-19 receiving the routine antiviral and hydroxychloroquine protocol: A randomized controlled clinical trial.
Topics: Acetylcysteine; Antiviral Agents; Atazanavir Sulfate; C-Reactive Protein; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Inflammation; Randomized Controlled Trials as Topic; Ritonavir; SARS-CoV-2 | 2023 |
3 other study(ies) available for atazanavir sulfate and hydroxychloroquine
| Article | Year |
|---|---|
Evolution and resolution of brain involvement associated with SARS- CoV2 infection: A close Clinical - Paraclinical follow up study of a case.
Topics: Adult; Anti-Bacterial Agents; Anticonvulsants; Atazanavir Sulfate; Betacoronavirus; Brain; Consciousness Disorders; Coronavirus Infections; COVID-19; Diffusion Magnetic Resonance Imaging; Disease Progression; Encephalitis; Female; Glucocorticoids; HIV Protease Inhibitors; Humans; Hydroxychloroquine; Immunoglobulins, Intravenous; Immunologic Factors; Intensive Care Units; Levetiracetam; Lung; Magnetic Resonance Imaging; Methylprednisolone; Pandemics; Pneumonia, Viral; Pons; Respiration, Artificial; SARS-CoV-2; Seizures; Temporal Lobe; Thalamus; Tomography, X-Ray Computed | 2020 |
Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir.
Topics: Adult; Aged; Antiviral Agents; Atazanavir Sulfate; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Female; Hospitalization; Humans; Hydroxychloroquine; Intensive Care Units; Length of Stay; Male; Middle Aged; Prospective Studies; Ritonavir; Severity of Illness Index; Time Factors; Treatment Outcome | 2020 |
Comparing Outcomes of Two Antiviral Therapy Combinations among COVID-19 Patients.
Topics: Aged; Antiviral Agents; Arrhythmias, Cardiac; Atazanavir Sulfate; Bilirubin; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Therapy, Combination; Female; Hospitalization; Humans; Hydroxychloroquine; Length of Stay; Lopinavir; Male; Middle Aged; Ritonavir; SARS-CoV-2; Treatment Outcome | 2022 |